Pharma's Love Affair With Dealmaking: No End In Sight
The pace of pharma dealmaking continued unabated in 2015, climaxing with Pfizer’s agreed $160 billion merger with Allergan. Conditions are right for this situation to persist, at least for the foreseeable future.
You may also be interested in...
Deal coincides with full year/fourth quarter earnings release.
Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth.
The merger of Pfizer and Allergan might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But it also has generated some angst over Allergan’s future as a stalwart in ophthalmology.